Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.36 |
| ▸ | MOGAT2 | Q3SYC2 | 5/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12740367 | 1.00 | CYP2C9 (0.36) | CYP2C9MOGAT2PTPN11CNR2CNR1 | |
| SCHEMBL12740368 | 1.00 | CYP2C9 (0.36) | CYP2C9MOGAT2PTPN11CNR2CNR1 | |
| SCHEMBL12740365 | 0.99 | FFAR4 (0.35) | CYP2C9MOGAT2PTPN11CNR2CNR1 | |
| SCHEMBL12740364 | 0.97 | FFAR4 (0.36) | CYP2C9MOGAT2FFAR4FFAR1NAAA | |
| SCHEMBL12736852 | 0.93 | PTPN11 (0.36) | CYP2C9MOGAT2PTPN11CNR2CNR1 | |
| SCHEMBL12736854 | 0.93 | PTPN11 (0.36) | CYP2C9MOGAT2PTPN11CNR2CNR1 | |
| SCHEMBL12736855 | 0.93 | PTPN11 (0.36) | CYP2C9MOGAT2PTPN11CNR2CNR1 | |
| SCHEMBL14767129 | 0.93 | FFAR4 (0.38) | CNR2CNR1FFAR4FFAR1NAAA | |
| SCHEMBL12736847 | 0.92 | FFAR4 (0.35) | CYP2C9MOGAT2PTPN11CNR2CNR1 | |
| SCHEMBL14766606 | 0.91 | FFAR4 (0.40) | FFAR4FFAR1NAAAS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | CYP2C9 2816/4885MOGAT2 992/4885PTPN11 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.